Lital Sever
Research Subjects
Lital Sever has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Adva Levy-Barda
Rabin Medical Center 2 Biobank, Department of Pathology Petah Tikva, Israel
19 shared publications - Amir Toporik
Computational Discovery, Compugen Ltd., Holon, Israel
19 shared publications - Ariella Jakobson-Setton
Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel
19 shared publications - Assaf Menachem
Preclinical Development, Compugen Ltd., Holon, Israel
19 shared publications - Aviram Mizrachi
Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medical College, Cornell University, New York, NY 10022, USA
19 shared publications - Dan Blat
Research & Drug Discovery, Compugen Ltd., Holon, Israel
19 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S5. IL-18BP blockade alters the immune infiltrate composition of E0771 tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S5. IL-18BP blockade alters the immune infiltrate composition of E0771 tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S4. Anti-IL-18BP Ab induced immunogenic memory response in E0771 tumor model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S4. Anti-IL-18BP Ab induced immunogenic memory response in E0771 tumor model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S1. IL-18BP is a potential soluble immune checkpoint in cancer.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S1. IL-18BP is a potential soluble immune checkpoint in cancer.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S3. Antitumor activity of anti-mouse-IL-18BP Ab in mice studies.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S3. Antitumor activity of anti-mouse-IL-18BP Ab in mice studies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S2. COM503 releases IL-18 activity in biochemical and functional assays.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S2. COM503 releases IL-18 activity in biochemical and functional assays.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S5. IL-18BP blockade alters the immune infiltrate composition of E0771 tumors.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S5. IL-18BP blockade alters the immune infiltrate composition of E0771 tumors.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S2. COM503 releases IL-18 activity in biochemical and functional assays.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S2. COM503 releases IL-18 activity in biochemical and functional assays.